Patent search ap:("Genmab A/S") AND inv:"Aran Frank Labrijn" Page 1

1.

发明授权
Bispecific antibodies against HER2 and CD3 有权

公开(公告)号：US11578141B2

公开(公告)日：2023-02-14

申请号：US16667369

申请日：2019-10-29

Applicant: GENMAB A/S

Inventor： Joost J. Neijssen , Joyce I. Meesters , Bart De Goeij , Aran Frank Labrijn , Paul Parren , Janine Schuurman

IPC: C07K16/46 , C07K16/10 , C07K16/28 , C07K16/32 , A61K47/68 , A61K39/395 , C07K1/113 , A61K39/00

Abstract: Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.

2.

发明授权
Monoclonal antibodies against c-Met 有权

公开(公告)号：US11512140B2

公开(公告)日：2022-11-29

申请号：US16548883

申请日：2019-08-23

Applicant: GENMAB A/S

Inventor： Joost J. Neijssen , Bart De Goeij , Edward Norbert Van Den Brink , Aran Frank Labrijn , Rene Hoet , Janine Schuurman , Paul Parren , Jan Van De Winkel

IPC: C07K16/30 , G01N33/574 , A61P35/00 , A61K39/395 , C07K16/28 , A61K45/06 , C07K16/40 , A61K39/00

Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

3.

发明授权
Inert format 有权

公开(公告)号：US11485796B2

公开(公告)日：2022-11-01

申请号：US16783720

申请日：2020-02-06

Applicant: GENMAB A/S

Inventor： Aran Frank Labrijn , Joyce I. Meesters , Joost J. Neijssen , Edward Norbert Van Den Brink , Janine Schuurman , Paul Parren

IPC: C07K16/00 , C07K16/40 , C07K16/28 , C07K16/10 , C07K16/36 , C07K16/32 , C07K16/12 , A61K39/00

Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

4.

发明授权
Recombinant IgG4 monovalent antibodies 有权

公开(公告)号：US10351629B2

公开(公告)日：2019-07-16

申请号：US15072983

申请日：2016-03-17

Applicant: GENMAB A/S

Inventor： Janine Schuurman , Tom Vink , Jan Van De Winkel , Aran Frank Labrijn , Paul Parren , Willem Karel Bleeker , Frank Beurskens , Patrick Van Berkel

IPC: C07K16/00 , A61K39/00 , C12N15/85 , C07K16/28

Abstract: The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.

5.

发明授权
Heterodimeric antibody Fc-containing proteins and methods for production thereof 有权

公开(公告)号：US11866514B2

公开(公告)日：2024-01-09

申请号：US16777053

申请日：2020-01-30

Applicant: GENMAB A/S

Inventor： Aran Frank Labrijn , Joyce I. Meesters , Ewald T. J. Van Den Bremer , Joost J. Neijssen , Patrick Van Berkel , Bart De Goeij , Tom Vink , Jan Van De Winkel , Janine Schuurman , Paul Parren

IPC: C07K16/46 , C07K16/10 , C07K16/28 , C07K16/32 , C07K16/40 , G01N33/68 , A61K39/00

CPC classification number: C07K16/468 , C07K16/1063 , C07K16/2809 , C07K16/2863 , C07K16/2887 , C07K16/32 , C07K16/40 , G01N33/6854 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/41 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94

Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.

6.

发明授权
Antibody variants having modifications in the constant region 有权

公开(公告)号：US10000570B2

公开(公告)日：2018-06-19

申请号：US14739768

申请日：2015-06-15

Applicant: Genmab A/S

Inventor： Aran Frank Labrijn , Stefan Loverix , Paul Parren , Jan Van De Winkel , Janine Schuurman , Ignace Lasters

IPC: C07K16/28 , C07K16/00 , A61K39/395 , A61K47/48 , A61K51/10 , A61K39/00

Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.

7.

发明授权
Monoclonal antibodies against c-Met 有权

公开(公告)号：US09657107B2

公开(公告)日：2017-05-23

申请号：US14721709

申请日：2015-05-26

Applicant: GENMAB A/S

Inventor： Joost J. Neijssen , Bart De Goeij , Edward Norbert Van Den Brink , Aran Frank Labrijn , Rene Hoet , Janine Schuurman , Paul Parren , Jan Van De Winkel

IPC: A61K39/395 , C07K16/30 , G01N33/574 , C07K16/28 , A61K45/06 , C07K16/40 , A61K39/00

CPC classification number: C07K16/3076 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/35 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/71 , C07K2317/74 , C07K2317/76 , C07K2317/92 , G01N33/5748 , G01N2333/912

Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

8.

发明授权
Monoclonal antibodies directed against programmed death-1 protein and their use in medicine 有权

公开(公告)号：US11932693B2

公开(公告)日：2024-03-19

申请号：US18315686

申请日：2023-05-11

Applicant: BioNTech SE , Genmab A/S

Inventor： Ugur Sahin , Sina Fellermeier-Kopf , Friederike Gieseke , Karsten Beckmann , Claudia Paulmann , Alexander Muik , Ivan Kuzmanov , Esther Cornelia Wilhelmina Breij , Patricia Garrido Castro , Jordan Blum , Lars Guelen , Joost Neijssen , Bart-Jan De Kreuk , Richard Hibbert , Janine Schuurman , Aran Frank Labrijn

IPC: C07K16/28

CPC classification number: C07K16/2818 , C07K2317/24 , C07K2317/92

Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.